← Back

Wire · operational-macro

FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA granted accelerated approval to neladalkib, a kinase inhibitor, for adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC), based on response rates observed in a single-arm clinical trial. This provides a new oral treatment option for patients who have received prior ALK tyrosine kinase inhibitors and chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new regulatory path open for oral treatments targeting ALK-positive lung cancer patients resistant to initial therapies. This approval signals increasing FDA willingness to back kinase inhibitors that address unmet needs in cancer care.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvallung-canceroncologytargeted-therapyaccelerated-approval